Interestingly, genetic deletion of Pak1, but not Pak2, in this model had partial beneficial effects on tumor growth and on hearing preservation, suggesting that PAK1 alone might prove a reasonably therapeutic for NF2-deficient malignancies, thus avoiding the cardiotoxicities associated with PAK2 inhibition. The gene discussed is PAK2; the disease is neoplasm.